Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5675-5680

  Alffenaar, Jan Willem C ^a   Bolhuis, Mathieu ^a   Van Hateren, Kai ^a   Sturkenboom, Marieke ^a   Akkerman, Onno ^a   De Lange, Wiel ^a   Greijdanus, Ben ^a   Van Der Werf, Tjip ^a   Touw, Daan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; N MONODESMETHYL BEDAQUILINE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CALIBRATION; CASE REPORT; CORRELATION COEFFICIENT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MASS SPECTROMETER; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUALITY CONTROL; SERUM; SPUTUM; TANDEM MASS SPECTROMETRY; THORAX RADIOGRAPHY; BLOOD; PROCEDURES; REPRODUCIBILITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

CHROMATOGRAPHY, LIQUID; DIARYLQUINOLINES; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84940933067     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00276-15     Document Type: Article

References (26)

1. Cox E, Laessig K. 2014. FDA approval of bedaquiline - the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 371:689-691. http://dx.doi.org/10.1056/NEJMp1314385.
2. Andries K, Verhasselt P, Guillemont J., Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
3. Rouan MC, Lounis N, Gevers T., Dillen L, Gilissen R, Raoof A., Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56:1444-1451. http://dx.doi.org/10.1128/AAC.00720-11.
4. van Heeswijk RPG, Dannemann B, Hoetelmans RMW. 2014. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69:2310-2318. http://dx.doi.org/10.1093/jac/dku171.
5. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55:169-177. http://dx.doi.org/10.1093/cid/cis353.
6. Pasipanodya JG, McIlleron H, Burger A., Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
7. Svensson E, Murray S, Karlsson M., Dooley K. 2015. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 70:1106-1114.
8. World Health Organization. 2013. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis Interim policy guidance, p 1-57. World Health Organization, Geneva, Switzerland.
9. Cuyckens F, Balcaen LIL, De Wolf K, De Samber B, Van Looveren C, Hurkmans R, Vanhaecke F. 2008. Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. Anal Bioanal Chem 390:1717-1729. http://dx.doi.org/10.1007/s00216-007-1761-6.
10. Balcaen LIL, De Samber B, De Wolf K, Cuyckens F, Vanhaecke F. 2007. Hyphenation of reverse-phase HPLC and ICP-MS for metabolite profiling - application to a novel antituberculosis compound as a case study. Anal Bioanal Chem 389:777-786. http://dx.doi.org/10.1007/s00216-007-1303-2.
11. Rustomjee R, Diacon AH, Allen J, Venter A., Reddy C, Patientia RF, Mthiyane TCP, De Marez T, Van Heeswijk R, Kerstens R, Koul A., De Beule K, Donald PR, McNeeley DF 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 52:2831-2835. http://dx.doi.org/10.1128/AAC.01204-07.
12. Matuszewski BK, Constanzer ML, Chavez-Eng CM.2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019-3030. http://dx.doi.org/10.1021/ac020361s.
13. Diacon AH, Pym A, Grobusch M., Patientia R, Rustomjee R, Page-Shipp L, Pistorius C., Krause R, Bogoshi M, Churchyard G., Venter A, Allen J, Palomino J.C., De Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
14. Srivastava S, Peloquin CA, Sotgiu G, Migliori GB 2013. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 42:1449-1453. http://dx.doi.org/10.1183/09031936.00073213.
15. Aarnoutse RRE, Sturkenboom MG, Robijns K, Harteveld A.R., Greijdanus B., Uges DR, Touw DJ, Alffenaar JW. 16 April 2015. An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J http://dx.doi.org/10.1183/09031936.00177014.
16. Angra PK, Taylor TH, Iademarco M.F., Metchock B., Astles JR, Ridderhof JC. 2012. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol 50:1233-1239. http://dx.doi.org/10.1128/JCM.06479-11.
17. Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero J.A., Carvalho ACC, Chang K-C, Codecasa L, Correia A., Crudu V, Davies P, Dedicoat M., Drobniewski F, Duarte R, Ehlers C., Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew W-W, Zellweger J-P, Cirillo DM. 2014. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:23-63. http://dx.doi.org/10.1183/09031936.00188313.
18. Cegielski J, Dalton T, Yagui M., Wattanaamornkiet W, Volchenkov G, van der Walt M, Tupasi T, Kcasnovsky C, Kuznetsiova T, Kurbutova E, Kummik T, Kuksa L, Kliiman K, Kiryanova E, Kim H, Kim C, Kazennyy B, Jou R, Huang W, Ershova J, Erokin V, Diem L, Contreras C, Chio S, Chernousova L, Chen M, Caoili J, Bayona J, Akksilp S, Global Preserving Effective TB Treatment Study (PETTS) Investigators. 2014. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59:1049-1063. http://dx.doi.org/10.1093/cid/ciu572.
19. Alffenaar J-WC, Gumbo T., Aarnoutse RE. 2015. Acquired drug resistance: we can do more than we think! Clin Infect Dis 60:969-970.
20. Merle CS, Fielding K, Sow O.B., Gninafon M., Lo MB, Mthiyane T, Odhiambo J, Amukoye E., Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C., Lapujade O, Olliaro PL, Lienhardt C. 2014. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:1588-1598. http://dx.doi.org/10.1056/NEJMoa1315817.
21. Jindani A, Harrison TS, Nunn A.J., Phillips PPJ, Churchyard GJ, Charalambous S, Hatherill M., Geldenhuys H, McIlleron HM, Zvada S.P., Mungofa S., Shah NA, Zizhou S, Magweta L, Shepherd J., Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson ALE, McHugh TD, Butcher PD, Mitchison DA. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599-1608. http://dx.doi.org/10.1056/NEJMoa1314210.
22. Gillespie SH, Crook AM, McHugh T.D., Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577-1587. http://dx.doi.org/10.1056/NEJMoa1407426.
23. Warner DF, Mizrahi V. 2014. Shortening treatment for tuberculosis - back to basics. N Engl J Med 371:1642-1643. http://dx.doi.org/10.1056/NEJMe1410977.
24. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM. 2015. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191:943-953. http://dx.doi.org/10.1164/rccm.201410-1801OC.
25. Grossman T, Shoen C, Jones S., Jones P, Cynamon M, Locher C. 2015. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother 59:1534-1541. http://dx.doi.org/10.1128/AAC.04271-14.
26. Philley J, Wallace RJ, Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. 12 February 2015, posting date. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest http://dx.doi.org/10.1378/chest.14-2764.